m+Medelevator.RU
← Поиск публикаций
International journal of pharmaceutics · 2025

Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Scialabba Cinzia, Corsaro Federico, Drago Salvatore Emanuele, Craparo Emanuela Fabiola, Cavallaro Gennara

Аннотация

In this study, we developed an inhalable Nano-in-Micro (NiM) system for localized delivery of Sorafenib (Sor) in non-small cell lung cancer (NSCLC) therapy. Sor was encapsulated into mucus-penetrating and folate-targeted polymeric nanoparticles (FA-PPP-NPs@Sor), produced starting from the α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), functionalised with poly(lactic-co-glycolic acid) (PLGA), and folate-conjugated polyethylene glycol (PEG-FA) FA (DDPLGA = 3.3  mol %, DDPEG-FA ≈ 8 chains/molecule). Nanoprecipitation produced 109  nm particles, easy to redisperse, with a DL of 10 wt%, which showed a controlled release of the drug, about 8.4 wt% (pH 7.4) vs. 21.7 wt% (pH 5.5) in 24  h. A selective cytotoxicity towards A549 lung cancer cells via folate receptor-mediated internalization was found, being IC50 = 18 ± 3.2  µM, significantly lower than those found both in 16HBE cells (IC50 = 69 ± 3.1  µM and free Sor (IC50 = 17.7 ± 2.3  µM). The receptor involvement was confirmed by competitive folate blocking, which raised IC50 >100  µM. Wound healing assay performed to evaluate the ability of Sor-loaded nanoparticles to inhibit or reduce cell migration showed 27 % vs. 40 % wound closure at 48  h (NiM vs Sor). The nanoparticles were further incorporated into inhalable microparticles via spray drying (SD), using mannitol, leucine, N-acetylcysteine, and ammonium bicarbonate as functional excipients (yield 63 wt%, EE = 100 wt%, DL = 0.35 wt%). The spray dried NiMSor microparticles exhibited a MMAD and a FPF, respectively, of 2.2  µm and 76 %, suitable for deep lung delivery. Furthermore, their storage at r.t. and dissolution in water reconstitutes the nanoparticle dispersion. Rheology tests demonstrated time- and concentration-dependent mucus thinning. Overall, this study presents a promising inhalable platform for targeted lung cancer therapy, combining targeted cytotoxicity, mucus penetration, controlled release, and favourable aerosol properties.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты